4 million women are treated for BV each year1 It’s estimated that only 50% of BV patients complete 5- to 7-day treatments2,3*

According to a national survey of HCPs who treat BV, reasons for patient nonadherence include4†:

Studies reveal that the longer and more complex a drug regimen is, the more it may lead to poor adherence and treatment failure2,5

BV treatments commonly require6-9:

  • Abstinence from drinking alcohol
  • 7 days of multiple pills
  • Messy creams and applicators
  • Using a back-up form of birth control

In a qualitative study, a majority of women said they felt frustrated and dissatisfied with current treatment regimens10

  • 91% of women would be open to trying new treatment options for their BV.11

Solosec® (secnidazole) dosing is as easy as: ONE PACKET. ONE DOSE. ONE TIME.12

Explore Dosing

Visit Next:

JUST ONE ORAL DOSE

Solosec® (secnidazole) may help your patients complete treatment.

Find out how

A compliance study of 71 patients randomized to oral (7 days) or intravaginal (5 days) treatment for bacterial vaginosis.3

The Harris Poll was conducted on behalf of Symbiomix Therapeutics, LLC, a Lupin Company, and the American Sexual Health Association (ASHA) among patients with BV and HCPs who treat BV within the U.S. (150 OB/GYNs, 151 board-certified nurse practitioners in women’s health, and OB/GYN physicians who see an average of 20+ BV patients a month) on March 1-15, 2018.4

REFERENCES:

  1. Chavoustie SE, Eder SE, Koltun WD, et al. Experts explore the state of bacterial vaginosis and the unmet needs facing women and providers. Int J Gynaecol Obstet. 2017;137(2):107-109.
  2. Schwebke JR, Morgan FG Jr, Koltun W, Nyirjesy P. A phase-3, double-blind, placebo-controlled study of the effectiveness and safety of single oral doses of secnidazole 2 g for the treatment of women with bacterial vaginosis. Am J Obstet Gynecol. 2017;217(6):678.e1-678.e9. doi: 10.1016/j.ajog.2017.08.017.
  3. Bartley JB, Ferris DG, Allmond LM, Dickman ED, Dias JK, Lambert J. Personal digital assistants used to document compliance of bacterial vaginosis treatment. Sex Transm Dis. 2004;31(8):488-491.
  4. Data on file. Bacterial Vaginosis Physician Survey. Symbiomix Therapeutics, LLC, a Lupin Company, and the American Sexual Health Association (ASHA). Prepared March 2018.
  5. Kardas P. Patient compliance with antibiotic treatment for respiratory tract infections. J Antimicrob Chemother. 2002;49:897-903.
  6. Centers for Disease Control and Prevention. Sexually transmitted diseases: treatment guidelines, 2015. Morbid Mortal Wkly Rep (MMWR). 2015;64(3):1-140.
  7. Broumas AG, Basara LA. Potential patient preference for 3-day treatment of bacterial vaginosis: responses to new suppository form of clindamycin. Adv Ther. 2000;17(3):159-166.
  8. Clindesse [prescribing information]. Allegan, MI: Perrigo Company, LLC; 2014.
  9. Data on File. Patient Research. Symbiomix, a Lupin company. 2013.
  10. Bilardi J, Walker S, McNair R, et al. Women’s management of recurrent bacterial vaginosis and experiences of clinical care: a qualitative study. PLoS One. 2016;11(3):e0151794. doi: 10.1371/journal.pone.0151794. eCollection 2016. Accessed August 23, 2017.
  11. Data on File. Bacterial Vaginosis Patient Survey. Symbiomix Therapeutics, LLC, a Lupin Company, and the American Sexual Health Association (ASHA). Prepared September 2017.
  12. Baraia ZA, Abdallah IM, Noor SA. Impact of educational program about self-care practices on the relieving of vaginal infection among high risk women in Ismailia City. IOSR J Nurs Health Sci. 2017;6(3):73-78.